Error loading player: No playable sources found

Player size: small large

AC24SAT06A

Updates to the Management of HR-Positive, HER2-Negative Breast Cancer

Date

April 6, 2024

Explore related products in the following collection:

Thumbnail for 2024 Annual Conference

2024 Annual Conference

Learning Objectives

Select evidence-based adjuvant treatment options for patients HR-positive and HER2-negative breast cancer based on risk of recurrence.
Integrate recent advances and available clinical data to optimally select and sequence agents in the treatment of HR-positive and HER2-negative metastatic breast cancer.

Speaker

William J. Gradishar, MD

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Related Products

Thumbnail for Updates in the Management of Neuroblastoma

Updates in the Management of Neuroblastoma

Use the 'Comments' tab to post questions for the speakers…

Thumbnail for Capturing Structured Data in the Electronic Health Record

Capturing Structured Data in the Electronic Health Record

Use the 'Comments' tab to post questions for the speakers…

Thumbnail for Basal Cell and Squamous Cell Skin Cancers: NCCN Guidelines® Updates Based on Risk Status

Basal Cell and Squamous Cell Skin Cancers: NCCN Guidelines® Updates Based on Risk Status

Thumbnail for Cancer Risk Reduction Strategies for Transgender, Non-Binary, and Gender Diverse People with Hereditary Cancer Syndromes

Cancer Risk Reduction Strategies for Transgender, Non-Binary, and Gender Diverse People with Hereditary Cancer Syndromes

Use the 'Comments' tab to post questions for the speakers…